Dan Burrows

Dan Burrows

InvestorPlace Feature Writer

Dan Burrows is a veteran of CBS MoneyWatch, DailyFinance, SmartMoney and Dow Jones MarketWatch, and has written for The Wall Street Journal, Consumer Reports and other publications. He favors value investing and writes about asset prices and macroeconomic trends for the long-term investor. He holds no individual securities.

Recent Articles

DuPont Stock: A Buy Amid Syngenta Talk? (DD, SYT)

By Dan Burrows, InvestorPlace Feature Writer

DuPont's (DD) agriculture division is large and unprofitable, so looking to combine it with a partner like Sygenta or Dow makes good sense.

Apple Goes Ex-Dividend, But the Big Money Is in Buybacks (AAPL)

By Dan Burrows, InvestorPlace Feature Writer

The Apple (AAPL) dividend yield almost looks like a joke because it's so low, but the share repurchase program is mammoth.

FireEye Inc (FEYE) Stock Plummets, But the Fall Isn’t Over Yet

By Dan Burrows, InvestorPlace Feature Writer

FireEye earnings were weaker than the market was expecting, and a smoking crater now occupies the space formerly reserved for FEYE stock.

5 Stocks to Buy for November

By Dan Burrows, InvestorPlace Feature Writer

Strong seasonality and favorable technicals suggest that these names are good fits for tactical investors.

Will Disney Earnings Crash DIS Stock Again?

By Dan Burrows, InvestorPlace Feature Writer

Star Wars may get all the hype, but ESPN will be in the spotlight when Disney stock reports earnings Thursday.

Buy Visa Stock Despite Its Big Deal and Earnings Miss (V)

By Dan Burrows, InvestorPlace Feature Writer

Visa stock was hurt by a $23 billion deal, a profit miss and a weak forecast, but the acquisition sets it up for more market-beating returns.

Ford’s Deep Holiday Discounts Offer Good Tidings for F Stock

By Dan Burrows, InvestorPlace Feature Writer

The market might be worried about Ford's margins, but F stock needs the car company to regain domestic market share, too.

Investors Should Cheer Pfizer’s Attempt to Buy Allergan (PFE, AGN)

By Dan Burrows, InvestorPlace Feature Writer

In a massive deal, Pfizer (PFE) would get increased growth from Allergan (AGN). It would be a huge boost to Pfizer stock and pharma.

Apple Earnings Bolster the Bull Case for AAPL Stock

By Dan Burrows, InvestorPlace Feature Writer

Apple earnings showed that AAPL has been unaffected by the slowdown in China and remains poised to have a solid holiday selling season.

5 Stocks to Sell for November

By Dan Burrows, InvestorPlace Feature Writer

November typically is good for the market, but poor seasonality and technical weakness put these stocks on top of most "sell" lists for right now.

Load More